uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Antagonists of IGF: Vitronectin Interactions Inhibit IGF-I-Induced Breast Cancer Cell Functions
Queensland Univ Technol, Tissue Repair & Regenerat Program, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia.;Univ Basel Hosp, Dept Biomed, Canc Immunol, Basel, Switzerland..
Queensland Univ Technol, Tissue Repair & Regenerat Program, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia..
Queensland Univ Technol, Tissue Repair & Regenerat Program, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia..
Queensland Univ Technol, Tissue Repair & Regenerat Program, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia..
Show others and affiliations
2016 (English)In: Molecular Cancer Therapeutics, ISSN 1535-7163, E-ISSN 1538-8514, Vol. 15, no 7, 1602-1613 p.Article in journal (Refereed) Published
Abstract [en]

We provide proof-of-concept evidence for a new class of therapeutics that target growth factor: extracellular matrix (GF: ECM) interactions for the management of breast cancer. Insulinlike growth factor-I (IGF-I) forms multiprotein complexes with IGF-binding proteins (IGFBP) and the ECM protein vitronectin (VN), and stimulates the survival, migration and invasion of breast cancer cells. For the first time we provide physical evidence for IGFBP-3: VN interactions in breast cancer patient tissues; these interactions were predominantly localized to tumor cell clusters and in stroma surrounding tumor cells. We show that disruption of IGF-I: IGFBP: VN complexes with L27-IGF-II inhibits IGF-I: IGFBP: VN-stimulated breast cancer cell migration and proliferation in two-and three-dimensional assay systems. Peptide arrays screened to identify regions critical for the IGFBP-3/-5: VN and IGF-II: VN interactions demonstrated IGFBP-3/-5 and IGF-II binds VN through the hemopexin-2 domain, and VN binds IGFBP-3 at residues not involved in the binding of IGF-I to IGFBP-3. IGFBP-interacting VN peptides identified from these peptide arrays disrupted the IGF-I: IGFBP: VN complex, impeded the growth of primary tumor-like spheroids and, more importantly, inhibited the invasion of metastatic breast cancer cells in 3D assay systems. These studies provide first-in-field evidence for the utility of small peptides in antagonizing GF: ECM-mediated biologic functions and present data demonstrating the potential of these peptide antagonists as novel therapeutics.

Place, publisher, year, edition, pages
2016. Vol. 15, no 7, 1602-1613 p.
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-303393DOI: 10.1158/1535-7163.MCT-15-0907ISI: 000381087200017PubMedID: 27196774OAI: oai:DiVA.org:uu-303393DiVA: diva2:971775
Available from: 2016-09-19 Created: 2016-09-19 Last updated: 2016-09-19Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Söderberg, Ola
By organisation
Molecular toolsScience for Life Laboratory, SciLifeLab
In the same journal
Molecular Cancer Therapeutics
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 18 hits
ReferencesLink to record
Permanent link

Direct link